,i #aahth ,,congress #ast ,session ,h4 ,r4 #def ,,in ,,the ,,house ,,of ,,representatives ,january #bd1 #bjbc,mr4 ,carter of ,georgia introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to amend the ,federal ,food1 ,drug1 and ,cosmetic ,act with respect to limitations on exclusive approval or licensure of orphan drugs1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,fairness in ,orphan ,drug ,exclusivity ,act4 #b4 ,limitations on exclusive approval or licensure of orphan drugs ,section #ebg of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj;cc7 is amended-- 7#a7 in subsection 7a71 by striking ,except as provided in subsection 7b7 and inserting ,except as provided in subsection 7b7 or 7f72 and 7#b7 by adding at the end the following3 7f7 ,limitations on exclusive approval1 certification1 or license 7#a7 ,in general ,for a drug designated under section #ebf for a rare disease or condition pursuant to the criteria set forth in subsection 7a77#b77;,b7 of such section1 the ,secretary shall not grant1 recognize1 or apply exclusive approval or licensure under subsection 7a71 and1 if such exclusive approval or licensure has been granted1 recognized1 or applied1 shall revoke such exclusive approval or licensure1 unless the sponsor of the application for such drug demonstrates with respect to an application approved or a license issued after the date of enactment of this subsection1 upon such approval or issuance1 that there is no reasonable expectation at the time of such approval or issuance that the cost of developing and making available in the ,united ,states such drug for such disease or condition will be recovered from sales in the ,united ,states of such drug1 taking into account all sales made or reasonably expected to be made within #ab years of first marketing the drug4 7#b7 ,considerations ,for purposes of paragraph 7#a71 the ,secretary and the sponsor of the application for the drug designated for a rare disease or condition described in such paragraph shall consider sales from all drugs that-- 7,a7 are developed or marketed by the same sponsor or manufacturer of the drug 7or a licensor1 predecessor in interest1 or other related entity to the sponsor or manufacturer72 and 7,b7 are covered by the same designation under section #ebf4 7#c7 ,criteria ,no drug designated under section #ebf for a rare disease or condition pursuant to the criteria set forth in subsection 7a77#b77;,b7 of such section shall be eligible for exclusive approval or licensure under this section unless it met such criteria under such subsection on the date on which the drug was approved or licensed4 4